Literature DB >> 27593744

Unilateral Subthalamic Nucleus Stimulation in the Treatment of Asymmetric Parkinson"s Disease with Early Motor Complications.

Michal Sobstyl1, Miroslaw Zabek, Artur Zaczynski, Wojciech Gorecki, Zbigniew Mossakowski, Grazyna Brzuszkiewicz-Kuzmicka.   

Abstract

AIM: The aim of this study was to assess the results of unilateral subthalamic nucleus (STN) stimulation for the treatment of Parkinson"s disease (PD) with marked asymmetry of parkinsonian motor symptoms and early motor complications.
MATERIAL AND METHODS: The clinical series consisted of 32 consecutive PD patients, in whom unilateral STN stimulation was performed. All patients were assessed according to the Unified Parkinson"s Disease Rating Scale (UPDRS), and Hoehn and Yahr staging. The patients were assessed preoperatively, and at 12, and 24 months after unilateral STN stimulation. 22 patients were followed for 2 years.
RESULTS: Medication off/stimulation on total UPDRS motor scores were improved by 29% when compared to the baseline medication off motor scores. The contralateral motor scores improved by 49%, whereas the axial motor scores by 18% in medication off/stimulation on condition. The duration and severity of levodopa induced dyskinesia were reduced respectively by 73% and by 77%. The daily levodopa dose was decreased by only 10%.
CONCLUSION: Unilateral STN stimulation is a safe and effective procedure for selected patients with marked asymmetry Parkinson"s disease motor symptoms and early motor complications.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27593744     DOI: 10.5137/1019-5149.JTN.14894-15.0

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  1 in total

1.  Clinical outcome prediction from analysis of microelectrode recordings using deep learning in subthalamic deep brain stimulation for Parkinson`s disease.

Authors:  Kwang Hyon Park; Sukkyu Sun; Yong Hoon Lim; Hye Ran Park; Jae Meen Lee; Kawngwoo Park; Beomseok Jeon; Hee-Pyoung Park; Hee Chan Kim; Sun Ha Paek
Journal:  PLoS One       Date:  2021-01-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.